Skip to main content
Premium Trial:

Request an Annual Quote

Quest Exercises Option on Clinical Genomics Colon Cancer Markers

NEW YORK (GenomeWeb News) – Australian firm Clinical Genomics today said that Quest Diagnostics has exercised an option to use the firm's gene-based biomarkers in the development of new tests for colon cancer.

Clinical Genomics didn't specify the markers but said that they are two genes that are associated with colorectal cancer and can be detected through blood testing. It also said that Quest intends to incorporate markers into future generations of its ColoVantage laboratory-developed test, which is currently based on the Septin9 biomarker and is offered to physicians in the US.

Terms of the license were not disclosed.

"Quest’s research and development expertise and national scale position it well to maximize the clinical potential of our gene markers as a testing service to aid colon cancer detection in the United States," Clinical Genomics CEO Lawrence LaPointe said in a statement.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.